Price Alert

Carisma Therapeutics Inc. (CARM)

NASDAQ: CARM · Real-Time Price · USD

0.45

-0.05 (-10.41%)

At close: Jun 20, 2025, 3:59 PM

-10.41% (1D)

Bid	0.44
Market Cap	18.75M
Revenue (ttm)	16.23M
Net Income (ttm)	-50.77M
EPS (ttm)	-1.22
PE Ratio (ttm)	-0.37
Forward PE	-0.68
Analyst	n/a

Ask	0.44
Volume	2,680,813
Avg. Volume (20D)	13,863,579
Open	0.48
Previous Close	0.50
Day's Range	0.43 - 0.56
52-Week Range	0.14 - 1.90
Beta	2.79

About CARM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CARM

Website n/a

Full Company Profile

Next Earnings Release

Carisma Therapeutics Inc. is scheduled to release its earnings on Aug 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

-25.65%

Carisma Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

9 months ago

-12.82%

Carisma Therapeutics shares are trading lower after Baird downgraded the stock from Outperform to Neutral and cut its price target from $10 to $1.

News

1 year ago · zacks.com

CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?

CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago · zacks.com

Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.

1 year ago · zacks.com

Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago.

1 year ago · zacks.com

Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago · zacks.com

Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now

CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among...

1 year ago · investorplace.com

3 Top Under-$5 Stocks for Strong Gains and Positive Outlook

To clearly set expectations from the get-go, these top stocks under $5 represent extraordinary risks. As either small or even micro-capitalization enterprises, you automatically should assume volatili...

2 years ago · zacks.com

Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know

The mean of analysts' price targets for Carisma Therapeutics Inc. (CARM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...